Semagludtide for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Mar 2021: Trial registered, NCT04777396
  2. 18 May 2021: Trial started, NCT04777396

The trials

NCT04777396: A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

State
Completed
Phase
Phase 3
People
1,840 taking part
Started
18 May 2021
Primary completion
16 Sep 2025
Arms
Oral Semaglutide
Results
None posted
  1. 2 Mar 2021: Trial registered
  2. 18 May 2021: Trial started
  3. 30 Jan 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.